These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20421983)

  • 21. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
    Betrouni N; Boukris S; Benzaghou F
    Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
    O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
    Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide.
    Haider MA; Davidson SR; Kale AV; Weersink RA; Evans AJ; Toi A; Gertner MR; Bogaards A; Wilson BC; Chin JL; Elhilali M; Trachtenberg J
    Radiology; 2007 Jul; 244(1):196-204. PubMed ID: 17507719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
    J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
    Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.
    Flegar L; Baunacke M; Buerk BT; Proschmann R; Zacharis A; Propping S; Huber J; Thomas C; Borkowetz A
    Urol Int; 2022; 106(9):903-908. PubMed ID: 34814157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide.
    Kelleher DK; Thews O; Scherz A; Salomon Y; Vaupel P
    Int J Oncol; 2004 Jun; 24(6):1505-11. PubMed ID: 15138594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Kleinclauss F; Frontczak A; Balssa L; Lebdai S; Azzouzi R
    Prog Urol; 2019; 29(8-9):393-401. PubMed ID: 31266699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
    Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
    Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonthermal Ablation by Using Intravascular Oxygen Radical Generation with WST11: Dynamic Tissue Effects and Implications for Focal Therapy.
    Kimm SY; Tarin TV; Monette S; Srimathveeravalli G; Gerber D; Durack JC; Solomon SB; Scardino PT; Scherz A; Coleman J
    Radiology; 2016 Oct; 281(1):109-18. PubMed ID: 26986047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast enhanced ultrasound imaging can predict vascular-targeted photodynamic therapy induced tumor necrosis in small animals.
    Cornelis FH; Kim K; Durack JC; Jebiwott S; Scherz A; Srimathveeravalli G; Coleman JA
    Photodiagnosis Photodyn Ther; 2017 Dec; 20():165-168. PubMed ID: 28887222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.
    Plaks V; Koudinova N; Nevo U; Pinthus JH; Kanety H; Eshhar Z; Ramon J; Scherz A; Neeman M; Salomon Y
    Neoplasia; 2004; 6(3):224-33. PubMed ID: 15153334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
    Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
    Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
    Betrouni N; Lopes R; Puech P; Colin P; Mordon S
    Phys Med Biol; 2011 Aug; 56(15):4771-83. PubMed ID: 21753234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Focal Laser Ablation and Photodynamic Vascular Therapy with soluble TOOKAD® in the treatment of low risk prostate cancer].
    Domínguez-Escrig JL; Casanova Ramón-Borja J
    Arch Esp Urol; 2016 Jul; 69(6):327-36. PubMed ID: 27416636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model.
    Mazor O; Brandis A; Plaks V; Neumark E; Rosenbach-Belkin V; Salomon Y; Scherz A
    Photochem Photobiol; 2005; 81(2):342-51. PubMed ID: 15623318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
    Lebdai S; Martin F; Bigot P; Azzouzi AR
    Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities.
    Weersink RA; Bogaards A; Gertner M; Davidson SR; Zhang K; Netchev G; Trachtenberg J; Wilson BC
    J Photochem Photobiol B; 2005 Jun; 79(3):211-22. PubMed ID: 15896648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019.
    Flegar L; Zacharis A; Aksoy C; Heers H; Derigs M; Eisenmenger N; Borkowetz A; Groeben C; Huber J
    World J Urol; 2022 Jul; 40(7):1645-1652. PubMed ID: 35562598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.
    Huang Z; Chen Q; Trncic N; LaRue SM; Brun PH; Wilson BC; Shapiro H; Hetzel FW
    Radiat Res; 2004 Jun; 161(6):723-31. PubMed ID: 15161347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.